Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90

Figures & data

Table 1 Distribution Characteristics of CR-ECO Specimens from 2017 to 2019

Specimen Type	2017		2018		2019
	N	P (%)	N	P (%)	N	P (%)
Urine	152	34.6	156	33.8	178	33.0
Sputum	132	30.0	126	27.3	161	29.8
Blood	44	10.0	48	10.4	39	7.2
Catheter	11	2.5	26	5.6	36	6.6
Secretion	15	3.4	28	6.0	29	5.3
Ascites	6	1.3	18	3.9	21	3.8
Pus	26	5.8	27	5.7	16	2.9
Bile	14	3.1	9	1.9	8	1.4
Drainage	1	0.2	4	0.8	12	2.2
Fecal	9	2.0	2	0.4	3	0.5
Vagina	7	1.5	0	0.0	1	0.1
Other	23	5.2	21	4.5	35	6.4
Total	439	100	461	100	539	100

Abbreviations: N, number; P, proportion.

Figure 1 Clinical distribution characteristics of CR-ECO. (A) Gender distribution characteristics of CR-ECO. (B) Distribution characteristics of CR-ECO departments. (C) Age distribution characteristics of CR-ECO.

Table 2 Regional Distribution Characteristics of CR-ECO Specimens from 2017 to 2019

Territory Name	Year			Total (N)	Proportion (%)
	2017 (N)	2018 (N)	2019 (N)
Shijiazhuang	145	142	158	445	30.92
Tangshan	107	113	121	341	23.70
Cangzhou	29	60	83	172	11.95
Handan	20	36	47	103	7.16
Xingtai	22	21	18	61	4.24
Chengde	28	18	14	60	4.17
Qinhuangdao	19	17	11	47	3.27
Zhangjiakou	7	7	32	46	3.20
Langfang	11	11	18	40	2.78
Total	439	461	539	1439	100

Abbreviation: N, number.

Table 3 Drug Sensitivity Data of CR-ECO to Various Antibacterial Drugs from 2017 to 2019

Antibiotic Name	2017			2018			2019			Average Value
	N	R (%)	S (%)	N	R (%)	S (%)	N	R (%)	S (%)	N	R (%)	S (%)
Ampicillin	346	95.1	3.5	339	97.1	1.2	471	97.2	1.7	1148	96.6	2.1
Piperacillin	278	91	5.8	220	91.8	3.2	226	94.7	4.4	719	92.5	4.6
Cefazolin	343	84.6	15.5	383	93.5	6.5	374	95.2	4.8	1092	91.3	8.7
Cefuroxime	315	88.9	9.8	343	92.1	6.4	353	92.6	6.8	1004	91.2	7.7
Ceftriaxone	322	87.6	12.1	305	93.1	6.2	375	93.9	5.6	996	91.6	7.9
Cefotaxime	167	81.4	18	153	92.8	7.2	140	91.4	8.6	458	88.2	11.6
Compound sulfamethoxazole	336	81	19	382	72.8	27.2	439	77.9	22.1	1149	76.9	23.1
Ciprofloxacin	349	80.8	16.3	408	87	11.5	477	85.3	10.9	1226	84.6	12.7
Levofloxacin	349	77.7	18.1	417	82.5	13.7	513	82.3	14	1271	81.0	15.1
Ampicillin/sulbactam	267	92.5	4.1	368	87.5	7.1	466	90.1	4.9	1093	89.8	5.5
Gentamicin	348	67	30.5	414	62.1	34.3	473	66.2	28.3	1227	65.0	30.9
Tobramycin	245	55.9	31.8	255	53.3	29.4	248	61.7	19.4	743	56.8	27.1
Aztreonam	283	82.3	15.2	236	77.5	19.9	286	82.5	16.4	801	81.0	17
Cefepime	352	84.9	13.4	426	84.5	10.6	514	87.2	8	1284	85.6	10.4
Ceftazidime	351	79.5	18.5	344	89	9.6	510	88	10	1197	85.7	12.4
Amoxicillin/clavulanic acid	137	39.4	49.6	97	89.7	8.2	120	86.7	9.2	353	69.1	24.6
Piperacillin/tazobactam	355	62.5	31.3	422	69	18.5	507	75.1	16.2	1276	69.5	21.2
Meropenem	361	62.3	32.7	402	74.9	17.9	472	78	18.2	1227	72.2	22.4
Imipenem	357	66.1	30.5	424	79.7	13	511	82.8	12.7	1284	77.3	17.8
Ertapenem	91	91.2	8.8	88	90.9	9.1	84	91.7	7.1	263	91.3	8.3
Amikacin	351	22.8	72.9	425	35.5	58.6	513	19.3	78.6	1281	22.2	70.6

Abbreviations: N, number of strains; R, drug resistance rate; S, sensitivity rate.

Table 4 CR-ECO MIC50 and MIC90 in 2017–2019

Antibiotic Name	Quantity	Break Point	MIC50	MIC90	MIC Range
Tigecycline	159	S≤0.03 R≥0.25	0.5	1	0.025–8
Ertapenem	262	S≤0.5 R≥2	2	8	0.12–32
Cefotaxime	458	S≤1 R≥4	64	64	0.12–128
Piperacillin	719	S≤16 R≥128	128	128	2–256
Tobramycin	743	S≤4 R≥16	16	16	0.5–32
Aztreonam	801	S≤4 R≥16	32	64	0.25–128
Ceftriaxone	996	S≤1 R≥4	64	128	0.25–128
Cefazolin	1092	S≤16 R≥32	32	64	2–128
Ampicillin/sulbactam	1093	S≤8 R≥32	32	64	2–128
Ampicillin	1148	S≤8 R≥32	32	64	2–128
Compound sulfamethoxazole	1149	S≤2 R≥4	8	16	0.25–32
Ceftazidime	1197	S≤4 R≥16	32	64	0.12–128
Ciprofloxacin	1226	S≤1 R≥4	4	4	0.06–32
Meropenem	1227	S≤1 R≥4	8	16	0.06–32
Gentamicin	1227	S≤4 R≥16	16	16	0.5–32
Levofloxacin	1271	S≤2 R≥8	8	16	0.12–16
Piperacillin/tazobactam	1276	S≤16 R≥128	128	128	1–256
Amikacin	1281	S≤16 R≥64	4	64	0.25–128
Cefepime	1284	S≤2 R≥16	32	64	0.12–128
Imipenem	1284	S≤1 R≥4	8	16	0.0625–64

Abbreviations: MIC, minimum inhibitory concentration; MIC50/MIC90, MIC50 and MIC90 can inhibit 50% or 90% of the tested bacteria.